LIVE NCPD WEBINAR: October 18, 2021, 5:00 PM – 6:00 PM Eastern Time

Fall Oncology Nursing Series

A Complimentary NCPD-Accredited Virtual Curriculum

Chimeric Antigen Receptor T-Cell Therapy in Chronic Lymphocytic Leukemia and Lymphomas

Register Now

Register for this complimentary event with the “Register Now ” button above,
which will take you to our Zoom registration page.

Event moderated by
Neil Love, MD
Research To Practice
Miami, Florida

Monday, October 18, 2021, 5:00 PM – 6:00 PM ET

Jeremy Abramson, MD
Director, Center for Lymphoma
Massachusetts General Hospital
Associate Professor of Medicine
Harvard Medical School
Boston, Massachusetts
Elizabeth Zerante, MS, AGACNP-BC
APN Inpatient Hematopoietic Cellular Therapy Service
University of Chicago Medicine
Chicago, Illinois


This activity is supported by an educational grant from Bristol-Myers Squibb Company.

Topics to Be Discussed

  • Overview, biologic rationale and mechanisms of action of CAR T-cell therapy
  • Process of producing and administering chimeric antigen receptor CAR T-cell therapies
  • Similarities and differences among approved and investigational CAR T-cell platforms
  • Spectrum, frequency, timing and severity of adverse events associated with CAR T-cell therapies, including cytokine release syndrome and neurologic toxicities; counseling patients and families about potential adverse events; effective management strategies
  • Selection and sequencing of CAR T-cell therapies for patients with DLBCL, FL and MCL
  • Design of, efficacy and safety in the pivotal studies of CD19-directed CAR T-cell therapy for diffuse large B-cell lymphoma, including ZUMA-1 (axicabtagene ciloleucel), JULIET (tisagenlecleucel) and TRANSCEND NHL 001 (lisocabtagene maraleucel), and for follicular lymphoma, including ZUMA-5 and TRANSCEND NHL 001 as well as for mantle cell lymphoma including ZUMA-2 (brexucabtagene Autoleucel)
  • Available efficacy and safety data and key ongoing studies of CD19-directed CAR T-cell therapy for chronic lymphocytic leukemia, including ZUMA-8 (axicabtagene ciloleucel) and TRANSCEND CLL 004 (lisocabtagene maraleucel); future investigational strategies

Target Audience
This activity has been designed to meet the educational needs of oncology nurses, nurse practitioners and clinical nurse specialists involved in the treatment of chronic lymphocytic leukemia and lymphomas.

Learning Objectives
Upon completion of this activity, participants should be able to

  • Develop an understanding of the scientific rationale for the development of chimeric antigen receptor (CAR) T-cell therapy as a targeted strategy to eliminate cancer cells, and appreciate the similarities and differences among commercially available and investigational products.
  • Appraise existing and emerging efficacy data from clinical trials of approved and investigational CAR T-cell therapies directed at CD19 for relapsed/refractory B-cell lymphomas, and use this information to identify patients who may be candidates for this approach.
  • Evaluate recently presented data documenting the benefit of CAR T-cell therapy for relapsed/refractory chronic lymphocytic leukemia (CLL), and educate patients regarding the potential clinical role of this strategy.
  • Recognize common adverse events associated with CAR T-cell therapies, and implement strategies to educate patients eligible for this treatment about the potential for these complications.
  • Recall ongoing research evaluating CAR T-cell-based approaches for various B-cell lymphomas, and CLL, and counsel appropriate patients regarding the potential benefits of trial participation.
Accreditation Statement
Research To Practice (RTP) is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s (ANCC) Commission on Accreditation.

NCPD Designation Statements
This educational activity for 1 contact hour is provided by RTP.

This activity is awarded 1 ANCC pharmacotherapeutic contact hour.

To obtain a certificate of completion and receive credit for this event, nurses must attend the entire activity and return a completed Educational Assessment and Credit Form. Credit form links will be emailed to participating nurses within 3 business days of the activity.

Oncology Nursing Certification Corporation (ONCC)/Individual Learning Needs Assessment (ILNA) Certification Information
The program content has been reviewed by the ONCC and is acceptable for recertification points. Learners must apply for NCPD credit to utilize this program for ONCC certification or renewal.

Unlabeled/Unapproved Uses Notice
There is no implied or real endorsement of any product by RTP or the ANCC. Any off-label use as declared by the FDA will be identified.

Content Validation and Disclosures
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

FACULTYMs Zerante has no relevant conflicts of interest to disclose. The following faculty reported relevant financial relationships with ineligible entities:

Dr AbramsonConsulting Agreements: AbbVie Inc, Allogene Therapeutics, AstraZeneca Pharmaceuticals LP, BeiGene Ltd, bluebird bio, Bristol-Myers Squibb Company, C4 Therapeutics, Celgene Corporation, Epizyme Inc, Genentech, a member of the Roche Group, Genmab, Incyte Corporation, Karyopharm Therapeutics, Kite, A Gilead Company, Kymera Therapeutics, MorphoSys, Mustang Bio, Novartis, Ono Pharmaceutical Co Ltd, Regeneron Pharmaceuticals Inc; Contracted Research: Bristol-Myers Squibb Company, Seagen Inc.

MODERATORDr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: AbbVie Inc, Adaptive Biotechnologies Corporation, ADC Therapeutics, Agios Pharmaceuticals Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Coherus BioSciences, Daiichi Sankyo Inc, Eisai Inc, Epizyme Inc, Exact Sciences Inc, Exelixis Inc, Five Prime Therapeutics Inc, Foundation Medicine, G1 Therapeutics Inc, Genentech, a member of the Roche Group, Genmab, Gilead Sciences Inc, GlaxoSmithKline, Grail Inc, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Natera Inc, Novartis, Novocure Inc, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sanofi Genzyme, Seagen Inc, Servier Pharmaceuticals LLC, Sumitomo Dainippon Pharma Oncology Inc, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, Tesaro, A GSK Company, TG Therapeutics Inc, Turning Point Therapeutics Inc and Verastem Inc.

RTP NCPD Planning Committee Members, Staff and Reviewers — Planners, scientific staff and independent reviewers for RTP have no relevant conflicts of interest to disclose.

This activity is supported by an educational grant from Bristol-Myers Squibb Company.